X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (53) 53
oncology (42) 42
male (39) 39
female (38) 38
middle aged (38) 38
aged (33) 33
index medicus (28) 28
adult (27) 27
treatment outcome (20) 20
lung neoplasms - drug therapy (19) 19
aged, 80 and over (18) 18
cancer (17) 17
neoplasm staging (15) 15
article (14) 14
kidney neoplasms - therapy (14) 14
carcinoma, non-small-cell lung - drug therapy (13) 13
carcinoma, renal cell - therapy (13) 13
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
immunotherapy (11) 11
lung neoplasms - pathology (11) 11
survival rate (11) 11
kidney neoplasms - pathology (10) 10
prognosis (10) 10
respiratory system (10) 10
chemotherapy (9) 9
antineoplastic agents - therapeutic use (8) 8
carcinoma, renal cell - pathology (8) 8
care and treatment (8) 8
kidney neoplasms - mortality (8) 8
lung cancer (8) 8
lung neoplasms - mortality (8) 8
solid tumors (8) 8
survival analysis (8) 8
therapy (8) 8
carcinoma, non-small-cell lung - mortality (7) 7
carcinoma, non-small-cell lung - pathology (7) 7
carcinoma, renal cell (7) 7
carcinoma, renal cell - immunology (7) 7
carcinoma, renal cell - mortality (7) 7
clinical trials (7) 7
kidney neoplasms - immunology (7) 7
nephrectomy (7) 7
retrospective studies (7) 7
survival (7) 7
urology & nephrology (7) 7
adenocarcinoma - drug therapy (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
dendritic cells - immunology (6) 6
disease-free survival (6) 6
docetaxel (6) 6
drug therapy (6) 6
follow-up studies (6) 6
interleukin-2 (6) 6
young adult (6) 6
carcinoma (5) 5
carcinoma, renal cell - secondary (5) 5
disease progression (5) 5
dose-response relationship, drug (5) 5
erlotinib (5) 5
expression (5) 5
hematology, oncology and palliative medicine (5) 5
immunology (5) 5
immunotherapy - methods (5) 5
interleukin-2 - therapeutic use (5) 5
lung cancer, non-small cell (5) 5
maximum tolerated dose (5) 5
medicine, research & experimental (5) 5
neoplasms - drug therapy (5) 5
neoplasms - pathology (5) 5
protein kinase inhibitors - therapeutic use (5) 5
pulmonary/respiratory (5) 5
renal cell carcinoma (5) 5
research (5) 5
trial (5) 5
adenocarcinoma (4) 4
animals (4) 4
antimitotic agents (4) 4
antineoplastic agents (4) 4
cancer research (4) 4
cancer vaccines - therapeutic use (4) 4
cell lung-cancer (4) 4
cisplatin (4) 4
classification (4) 4
combination (4) 4
combined modality therapy (4) 4
flt3 ligand (4) 4
gefitinib (4) 4
growth (4) 4
interleukin-4 - administration & dosage (4) 4
kidney (4) 4
medicine & public health (4) 4
necrosis-factor-alpha (4) 4
neoplasm metastasis (4) 4
neoplasm recurrence, local - drug therapy (4) 4
non-small cell lung cancer (4) 4
open-label (4) 4
paclitaxel (4) 4
phenotype (4) 4
pulmonary and respiratory medicine (4) 4
quinazolines - therapeutic use (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cancer Research, ISSN 0008-5472, 11/2015, Volume 75, Issue 22 Supplement 1, pp. A1 - A1-36
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. TPS11110 - TPS11110
Journal Article
Future oncology (London, England), 10/2014, Volume 10, Issue 12, p. 1913
Microtubule antagonists are highly active agents for treatment of metastatic lung cancer, but can lead to significant toxicities and tumor resistance. Eribulin... 
Ketones - pharmacology | Lung Neoplasms - drug therapy | Animals | Tubulin Modulators - pharmacology | Furans - pharmacology | Humans | Antineoplastic Agents - pharmacology
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2018, Volume 36, Issue 14, pp. 1412 - 1418
PurposeThis multinational study evaluated the antitumor activity of nivolumab in nasopharyngeal carcinoma (NPC). Tumor and plasma-based biomarkers were... 
THERAPY | MELANOMA | BARR-VIRUS DNA | ONCOLOGY | PD-L1 EXPRESSION | MUTATIONS | BLOCKADE | CANCER | SUBSET | CELL CARCINOMA | ESCAPE | ORIGINAL REPORTS
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2001, Volume 19, Issue 6, pp. 1649 - 1657
Journal Article
Cancer Discovery, ISSN 2159-8274, 06/2016, Volume 6, Issue 6, pp. 601 - 611
Journal Article
Journal Article
Future Oncology, ISSN 1479-6694, 10/2014, Volume 10, Issue 12, pp. 1913 - 1924
Microtubule antagonists are highly active agents for treatment of metastatic lung cancer, but can lead to significant toxicities and tumor resistance. Eribulin... 
lung cancer | antimicrotubule | halichondrin | eribulin | taxanes | HALICHONDRIN-B | MECHANISM | MESYLATE E7389 | NATURAL-PRODUCTS | PHASE-II | ONCOLOGY | DYNAMICS | TUBULIN | CELL | BINDING
Journal Article
Lung Cancer, ISSN 0169-5002, 2017, Volume 106, pp. 110 - 114
Highlights • SCLC transformation is a resistance mechanism to ALK inhibitors. • Liquid biopsy missed morphologic examination. • Emergence of Rb1 C706Y and p53... 
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | Small cell lung cancer transformation | ALK G1202R solvent front mutation | Lorlatinib | Rb1 C706Y | Circulating tumor DNA | ALK+ NSCLC | ADENOCARCINOMA | EML4-ALK FUSION | ACQUIRED-RESISTANCE | 1ST | ALK plus NSCLC | ONCOLOGY | RESPIRATORY SYSTEM | ALECTINIB | Rbl C706Y | Lung Neoplasms - drug therapy | Humans | Lung Neoplasms - metabolism | Middle Aged | Lung Neoplasms - pathology | Male | Small Cell Lung Carcinoma - drug therapy | Small Cell Lung Carcinoma - metabolism | Cell Transformation, Neoplastic - genetics | Fatal Outcome | Adult | Female | Lactams, Macrocyclic - administration & dosage | Lactams, Macrocyclic - therapeutic use | Retinoblastoma Binding Proteins - genetics | Carcinoma, Non-Small-Cell Lung - pathology | Pyridines | Neoplastic Cells, Circulating - drug effects | Liquid Biopsy - methods | Pyrazoles | Carcinoma, Non-Small-Cell Lung - metabolism | Disease Progression | Drug Resistance, Neoplasm - genetics | Small Cell Lung Carcinoma - pathology | Receptor Protein-Tyrosine Kinases - genetics | Protein Kinase Inhibitors - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Ubiquitin-Protein Ligases - genetics | Tumor proteins | Medical colleges | Genetic aspects | Development and progression | Lung cancer, Small cell | Lung cancer, Non-small cell
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. 9083 - 9083
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 02/2012, Volume 18, Issue 4, pp. 1092 - 1100
Journal Article
Frontiers in Oncology, ISSN 2234-943X, 2013, Volume 3, p. 135
Epigenetic deregulation of gene function has been strongly implicated in carcinogenesis and is one of the mechanisms contributing to the development of lung... 
DNA methylation | Epigenetics | Histone deacetylase inhibitors | Lung cancer | MicroRNAs | Hypomethylating agent | lung cancer | DNA Methylation | Histone deacetylase inhibitor | Hypomethylating Agent | epigenetics
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.